The Centre for Probe Development and Commercialization (CPDC) has entered into a production, manufacturing and supply agreement with a South Korean company, CellBion, for a new treatment of prostate cancer, Lu-177-radiolabelled PSMA (DGUL), according to a news release.
The treatment is currently in Phase II clinical trials in South Korea, the news release said.
"We are delighted to be working with CPDC and to offer our product, Lu-177-PSMA (DGUL), to the North American market," said Dr. Kweon Kim, CEO of CellBion. "We are impressed with the caliber of work and the professionalism provided by the entire CPDC team and very much look forward to the successful delivery of our program in order to provide clinical supply of our lead product in South Korea and extend it to North America."
CellBion's program will benefit from the "unique value proposition that CPDC offers," the center said.
"We are very excited to be working with CellBion," said Dr. Bruno Paquin, the center's CEO. "CPDC has an excellent track record at manufacturing and supplying radiopharmaceuticals for multiple international clients. Expanding our portfolio in Asia is a significant milestone as we thrive to support our partners from early clinical development to commercial manufacturing."
The center is based in Hamilton, Canada.
"CPDC is a global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and the Ontario Institute for Cancer Research (OICR)," the news release said.